Tactile Systems Technology, Inc.
TCMDHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tactile Systems Technology, Inc. focuses on Medical Devices services and products. Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. The company carries a $495.4M market cap, placing it firmly in the small-cap category. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.
Market Cap
$495.4M
Beta
0.79
P/E (TTM)
20.44
P/E (Fwd)
15.03
EPS (TTM)
$1.07
EPS (Fwd)
$1.46
ROE
11.9%
ROA
7.9%
Cash
$69.9M
Total Debt
$14.4M
Free CF
$14.5M
52W Change
59.8%
Annual Financials
Cash vs Debt
Where TCMD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, TCMD finished 16.23% below its 150-day moving average ($26.56) and 17.41% below its 200-day moving average ($26.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TCMD overbought or oversold?
At the September 2, 2026 close, TCMD's RSI(14) was 28.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $69.9M in cash and $14.4M in debt, TCMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $14.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.9% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $246.8M (2022) to $329.5M (2025), reflecting a 34% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TCMD.